One of the aims of ovarian cancer biomarkers is to detect by simple methods, ideally a serum assay, women that should be considered as candidates for a surgical approach. SC, as expected. B. PLA assay was performed using the Duolink in situ Detection Reagents Fluorescence (Olink? Bioscience, Gracillin Uppsala, Sweden) according to the manufacturer’s instructions. The concentration for primary antibodies and PLA probes were the same described in material and methods. Our results show that MUC16 is a carrier of STn, Tn and T in OVCAR3 WT and that MUC16/STn and MUC16/Tn increase in OVCAR\3 SC, whereas MUC16/T is completely negative. The IF and PLA staining were observed with a Zeiss microscope (Imager Z1), and images were acquired using the Axiovision software at 200 magnification. Scale bar, 20?m. Samples were examined under a Zeiss Imager.Z1 Axio fluorescence microscope equipped with DAPI and Texas Red filters. Images were acquired using a Zeiss Axio cam MRm and the AxioVision Rel 4.8 software. The resulting images were modified using ImageJ software as follows: background with radius 4 was subtracted from the red channel of the RGB images and a maximum filter with radius 1 was applied. The result was intensity\scaled to suit printing details. MOL2-9-503-s002.jpg (129K) GUID:?49A0977A-F19B-46FB-8DD5-C5E954E16B32 Supplementary Figure?S3 Glyco\mucin profiles were evaluated in serial sections from three different cases. PLA assays show different profiles of overlap or absence of overlap. In the first example (A,B) we show an area where Tn is carried by MUC16 (B, 20) but not by MUC 1 (A, 20). In the second case (C,D) we show an area where STn is carried by MUC1 (C, 10, insert 40) but not by MUC 16 (D, 10, insert 40). Finally, in the third case (E,F) there is complete overlap between expression of STn in MUC1 (E, 40) and in MUC16 (F, 40). MOL2-9-503-s003.jpg (165K) GUID:?6410477E-D351-46DB-AFC0-7C65ECCDB29F Abstract The CA125 assay detects circulating MUC16 and is one of the most widely used cancer biomarkers for the follow\up of ovarian cancer. We previously demonstrated that detection of aberrant cancer\associated Gracillin glycoforms of MUC16 as well as MUC1 in circulation could improve the yield of these serum assays. Our aim was to refine ovarian cancer biomarkers by detection of aberrant glycoforms (Tn, STn, and T) of MUC16 and MUC1 in ovarian cancer tissue using Proximity Ligation Assays (PLA). We studied two series of serous ovarian tumours, a pilot series of 66 Gracillin ovarian tumours (27 cystadenomas, 16 borderline tumours and 23 adenocarcinomas) from Centro Hospitalar S. Jo?o, Porto and a validation series of 89 ovarian tumours (17 cystadenomas, 25 borderline tumours and 47 adenocarcinomas) from the Portuguese Institute of Oncology Francisco Gentil, Lisbon. PLA reactions for MUC16/Tn, Gracillin MUC16/STn, MUC1/Tn and MUC1/STn were negative in benign lesions but often positive in borderline and malignant lesions, in both series. An even better yield was obtained based on WIF1 positivity for any of the four glyco\mucin profiles, further increasing sensitivity to 72% and 83% in the two series, respectively, with 100% specificity. The strategy is designated glyco\mucin profiling and provides strong support for development of PLA\based serum assays for early diagnosis. (pH 6.0) (CE IVD by Gracillin Thermo Scientific Detection Reagents Brightfield (Olink? Bioscience, Uppsala, Sweden) according to the manufacturer’s instructions. Briefly, after deparaffinization and heat\induced antigen retrieval, tissue slides were incubated with hydrogen peroxide 3% followed by incubation at 37?C for 30?min with blocking solution in a humidity chamber. The mAbs used to.